Prevalence and Outcomes of Medium Vessel Occlusions With Discrepant Infarct Patterns.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
09 2020
Historique:
pubmed: 8 8 2020
medline: 31 10 2020
entrez: 8 8 2020
Statut: ppublish

Résumé

The prognosis of medium vessel occlusions (MeVOs), that is, M2/3 middle cerebral artery, A2/3 anterior cerebral artery, and P2/3 posterior cerebral artery occlusions, is generally better compared with large vessel occlusions, since brain ischemia is less extensive. However, in some MeVO patients, infarcts are seen outside the territory of the occluded vessel (MeVO with discrepant infarcts). This study aims to determine the prevalence and clinical impact of discrepant infarct patterns in acute ischemic stroke due to MeVO. We pooled data of MeVO patients from INTERRSeCT (Identifying New Approaches to Optimize Thrombus Characterization for Predicting Early Recanalization and Reperfusion With IV Alteplase and Other Treatments Using Serial CT Angiography) and PRove-IT (Precise and Rapid Assessment of Collaterals Using Multi-Phase CTA in the Triage of Patients With Acute Ischemic Stroke for IA Therapy)-2 prospective cohort studies of patients with acute ischemic stroke. The combination of occlusion location on baseline computed tomography angiography and infarct location on follow-up computed tomography/magnetic resonance imaging was used to identify MeVOs with discrepant infarct patterns. Two definitions for discrepant infarcts were applied; one was more restrictive and purely based on infarct patterns of the basal ganglia, whereas the second one took cortical infarct patterns into account. Clinical outcomes of patients with versus without discrepant infarcts were summarized using descriptive statistics. Logistic regression was performed to obtain adjusted effect size estimates for the association of discrepant infarcts and good outcome, defined as a modified Rankin Scale score of 0 to 2, and excellent outcome (modified Rankin Scale score 0-1). Two hundred sixty-two patients with MeVO were included in the analysis. The prevalence of discrepant infarcts was 39.7% (definition 1) and 21.0% (definition 2). Patients with discrepant infarcts were less likely to achieve good outcome (definition 1: adjusted odds ratio, 0.48 [95% CI, 0.25-0.91]; definition 2: adjusted odds ratio, 0.47 [95% CI, 0.22-0.99]). When definition 1 was applied, patients with discrepant infarcts were also less likely to achieve excellent outcome (definition 1: adjusted odds ratio, 0.55 [95% CI, 0.31-0.99]; definition 2: adjusted odds ratio, 0.62 [95% CI, 0.31-1.25]). MeVO patients with discrepant infarcts are common, and they are associated with more severe deficits and poor outcomes.

Sections du résumé

BACKGROUND AND PURPOSE
The prognosis of medium vessel occlusions (MeVOs), that is, M2/3 middle cerebral artery, A2/3 anterior cerebral artery, and P2/3 posterior cerebral artery occlusions, is generally better compared with large vessel occlusions, since brain ischemia is less extensive. However, in some MeVO patients, infarcts are seen outside the territory of the occluded vessel (MeVO with discrepant infarcts). This study aims to determine the prevalence and clinical impact of discrepant infarct patterns in acute ischemic stroke due to MeVO.
METHODS
We pooled data of MeVO patients from INTERRSeCT (Identifying New Approaches to Optimize Thrombus Characterization for Predicting Early Recanalization and Reperfusion With IV Alteplase and Other Treatments Using Serial CT Angiography) and PRove-IT (Precise and Rapid Assessment of Collaterals Using Multi-Phase CTA in the Triage of Patients With Acute Ischemic Stroke for IA Therapy)-2 prospective cohort studies of patients with acute ischemic stroke. The combination of occlusion location on baseline computed tomography angiography and infarct location on follow-up computed tomography/magnetic resonance imaging was used to identify MeVOs with discrepant infarct patterns. Two definitions for discrepant infarcts were applied; one was more restrictive and purely based on infarct patterns of the basal ganglia, whereas the second one took cortical infarct patterns into account. Clinical outcomes of patients with versus without discrepant infarcts were summarized using descriptive statistics. Logistic regression was performed to obtain adjusted effect size estimates for the association of discrepant infarcts and good outcome, defined as a modified Rankin Scale score of 0 to 2, and excellent outcome (modified Rankin Scale score 0-1).
RESULTS
Two hundred sixty-two patients with MeVO were included in the analysis. The prevalence of discrepant infarcts was 39.7% (definition 1) and 21.0% (definition 2). Patients with discrepant infarcts were less likely to achieve good outcome (definition 1: adjusted odds ratio, 0.48 [95% CI, 0.25-0.91]; definition 2: adjusted odds ratio, 0.47 [95% CI, 0.22-0.99]). When definition 1 was applied, patients with discrepant infarcts were also less likely to achieve excellent outcome (definition 1: adjusted odds ratio, 0.55 [95% CI, 0.31-0.99]; definition 2: adjusted odds ratio, 0.62 [95% CI, 0.31-1.25]).
CONCLUSIONS
MeVO patients with discrepant infarcts are common, and they are associated with more severe deficits and poor outcomes.

Identifiants

pubmed: 32757752
doi: 10.1161/STROKEAHA.120.030041
doi:

Substances chimiques

Fibrinolytic Agents 0
Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2817-2824

Auteurs

Johanna M Ospel (JM)

Departments of Clinical Neurosciences (J.M.O., P.C., M.M., A.M., M.H., M.A.A., M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.
Department of Radiology, University Hospital of Basel, Switzerland (J.M.O.).

Petra Cimflova (P)

Departments of Clinical Neurosciences (J.M.O., P.C., M.M., A.M., M.H., M.A.A., M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.
Department of Medical Imaging (P.C.), St. Anne's University Hospital Brno, Czech Republic.
International Clinical Research Center (P.C.), St. Anne's University Hospital Brno, Czech Republic.
Faculty of Medicine, Masaryk University, Brno, Czech Republic (P.C.).

Martha Marko (M)

Departments of Clinical Neurosciences (J.M.O., P.C., M.M., A.M., M.H., M.A.A., M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.

Arnuv Mayank (A)

Departments of Clinical Neurosciences (J.M.O., P.C., M.M., A.M., M.H., M.A.A., M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.

Moiz Hafeez (M)

Departments of Clinical Neurosciences (J.M.O., P.C., M.M., A.M., M.H., M.A.A., M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.

Mohammed A Almekhlafi (MA)

Departments of Clinical Neurosciences (J.M.O., P.C., M.M., A.M., M.H., M.A.A., M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.
Radiology (M.A.A., M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.

Michael D Hill (MD)

Departments of Clinical Neurosciences (J.M.O., P.C., M.M., A.M., M.H., M.A.A., M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.
Radiology (M.A.A., M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.

Andrew M Demchuk (AM)

Departments of Clinical Neurosciences (J.M.O., P.C., M.M., A.M., M.H., M.A.A., M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.
Radiology (M.A.A., M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.

Bijoy K Menon (BK)

Departments of Clinical Neurosciences (J.M.O., P.C., M.M., A.M., M.H., M.A.A., M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.
Radiology (M.A.A., M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.

Mayank Goyal (M)

Departments of Clinical Neurosciences (J.M.O., P.C., M.M., A.M., M.H., M.A.A., M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.
Radiology (M.A.A., M.D.H., A.M.D., B.K.M., M.G.), University of Calgary, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH